Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

MRSN - Mersana Therapeutics Inc


IEX Last Trade
1.57
0.050   3.185%

Share volume: 479,849
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$1.52
0.05
3.29%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
25%
Profitability 25%
Dept financing 19%
Liquidity 65%
Performance 15%
Company vs Stock growth
vs
Performance
5 Days
1.28%
1 Month
-20.60%
3 Months
-34.17%
6 Months
-67.42%
1 Year
29.51%
2 Year
-79.35%
Key data
Stock price
$1.57
P/E Ratio 
-1.85
DAY RANGE
N/A - N/A
EPS 
-$0.86
52 WEEK RANGE
$1.07 - $6.28
52 WEEK CHANGE
$0.32
MARKET CAP 
193.827 M
YIELD 
N/A
SHARES OUTSTANDING 
122.675 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/12/2024
BETA 
1.83
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$903,740
AVERAGE 30 VOLUME 
$1,154,017
Company detail
CEO: Anna Protopapas
Region: US
Website: http://www.mersana.com/
Employees: 255
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

mersana is rewriting the rules for immunoconjugate therapies by leveraging our fleximer platform to create precisely targeted and highly tailored drugs that radically improve patients’ lives. our fleximer platform allows us to custom design an adc with specific properties to overcome limitations of current adc approaches and increase the drug’s chances of effectively attacking a particular cancer. we engineer immunoconjugates to deliver industry-leading payloads of an array of anti-tumor agents directly to cancerous cells, controlling when, where and how those agents are released. because we can safely deliver higher quantities of therapeutic payloads directly to a tumor, mersana’s adc therapies have the potential to more effectively treat broader populations of cancer patients while significantly reducing the side effects associated with many of today’s cancer treatments.

Recent news